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Abstract
Background: This study was performed to compare levels of serum homocysteine (Hcy), vitamin
B12 and folic acid in patients with primary open-angle glaucoma (POAG), pseudoexfoliative
glaucoma (PEXG), normotensive glaucoma (NTG) and healthy controls.
Methods: Twentyfive patients with POAG, 24 with PEXG, and 18 with NTG, along with 19
control healthy subjects were included this prospective study. Levels of serum Hcy were measured
using immunoassay, and those of serum vitamin B12 and folic acid were measured using competitive
chemiluminescent enzyme immunoassay.
Results: The mean Hcy concentration in the PEXG group was significantly higher (P < 0.001) as
compared to the other groups. There were no significant differences with respect to the mean Hcy
concentrations among other groups (P > 0.05). There were no statistical differences in serum
vitamin B12 levels among POAG, PEXG, NTG and control subjects (P > 0.05).
The mean serum folic acid level was significantly lower in the subjects with PEXG (P < 0.009).
However, the mean folic acid concentrations among the other groups did not differ significantly (P
> 0.05).
Conclusion: Elevated levels of Hcy in PEXG may explain the role of endothelial dysfunction among
patients with PEXG.
Background
Intraocular pressure (IOP) is assumed to be the most sig-
nificant risk factor in glaucoma, but recent evidences indi-
cate that vascular risk factors may also play a role.
Impaired microcirculation and abnormal perfusion may
cause glaucomatous damage in the optic nerve head. Ana-
tomical or functional abnormalities of the vessels of the
optic nerve head such as arteriosclerosis or vascular dys-
regulation might be the causative factor [1,2].
The metabolism of methionine via homocysteine (Hcy)
to cysteine is a complex pathway involving an enzyme
depending on vitamin B12, B6, and folic acid. Genetically
inherited defects are the most important determinants of
elevated levels of Hcy. Some studies showed that elevated
Hcy may increase the risk of retinal vascular diseases, such
as retinal artery and vein occlusion and non-artheritic
ischemic optic neuropathy [3-7]. Hcy-induced vascular
problem may be a multifactorial case, including direct
toxic damage to the endothelium, stimulation of prolifer-
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ation of smooth muscle cells, enhanced low density lipo-
protein peroxidation, increased platelet aggregation, and
effects upon the coagulation system [8].
According to one study, serum Hcy concentrations in
patients with vascular disease are on average 30% higher
than in normal subjects [9]. In addition, mild hyperho-
mocysteinemia might be a risk factor for myocardial inf-
arction, stroke, abdominal aorta aneurysms and vascular
dementia [10-13].
Recently, higher levels of plasma Hcy in primary open-
angel glaucoma (POAG) and pseudoexfoliative glaucoma
(PEXG) patients were reported [14-18]. On the other
hand, some studies reported no significant differences in
levels of plasma Hcy in POAG and normotensive glau-
coma (NTG) [16,18,19].
The aim of this study is to evaluate the role of serum Hcy,
vitamin B12 and folic acid levels in patients with POAG,
PEXG, and NTG, and compare them to sex and age-
matched group of control healthy subjects.
Methods
Total of 25 patients with POAG, 24 with PEXG, and 18
with NTG, along with 19 control healthy subjects under-
going ocular surgery at the Gaziosmanpas ¸a University,
Department of Ophthalmology between October 2004
and May 2005 were enrolled in this case control study.
The study was conducted according to the tenets of the
Declaration of Helsinki, and patients gave informed con-
sent after the nature and intent of the study had been fully
explained to them.
All patients underwent a complete ophthalmic examina-
tion, including visual acuity, slit-lamp examination, goni-
oscopy, tonometry, fundoscopy, visual field examination,
and systemic examination.
Inclusion criteria were as follows:
1-POAG was defined by the presence of an open angle on
gonioscopy, IOP ≥ 22 mmHg measured with a Goldman
Applanation Tonometer, typical glaucomatous cupping
and visual field defect in at least one eye on standard auto-
mated perimetry (full-threshold or Swedish Interactive
Threshold Algorithm (SITA) strategy, program 24-2,
Humphrey Field Analyzer).
2-Diagnosis of PEXG was based on the presence of typical
exfoliation material on the anterior lens capsule in one or
both eyes with typical glaucomatous cupping and visual
field defect in at least one eye. IOP was ≥22 mmHg with
an open angle in gonioscopic examination.
3-NTG patients were characterized by the presence of
glaucomatous optic neuropathy and visual field defect in
at least one eye and IOP was <22 mmHg.
4-Control subjects had no history of elevated IOP higher
than 22 mmHg, no exfoliative material on the anterior
lens capsule, normal visual fields and optic discs.
Exclusion criteria included non-genetic factors associated
with hyperhomocysteinemia, a history of diabetes melli-
tus, systemic hypertension, peripheral or coronary artery
disease, cerebrovascular disease, renal dysfunction, ocular
inflammation, retinal occlusive disease. In addition, we
excluded those taking vitamin and other medications
known to affect Hcy measurements, such as phenytoin,
methotrexate, vitamins B6, B12 and folic acid.
Serum total hcy, vitamin B12 and folic acid analysis
A single 5-ml venous blood sample for serum Hcy, vita-
min B12 and folic acid detection was collected in the fast-
ing state. The samples were centrifuged within 1 h after
collection and stored at -40°C. The levels of serum Hcy
were measured using an immunoassay procedure (Immu-
lite 2000-BIODPC, USA). This assay gives normal values
of the serum Hcy as 12–15 µmol/l according to the man-
ufacturer. The levels of serum vitamin B12 and folic acid
were measured using competitive chemiluminescent
enzyme immunoassay (Immulite 2000-BIODPC, USA).
For these assays, the normal serum values of vitamin B12
and folic acid are, respectively, 193–982 pg/ml and 3–7
ng/ml, also according to manufacturer's instruction.
Statistical analysis
Analysis of variance (one-way ANOVA) was used to detect
differences in continuous variables (Hcy, vitamin B12 and
folic acid, age) among the 4 study groups. For categorical
variables (gender), chi-square tests was used to assess dif-
Table 1: Demographic data characteristics of the study groups. POAG: primary open-angel glaucoma PEXG: pseudoexfoliative 
glaucoma, NTG: normotensive glaucoma, SD: standard deviation.
POAG (n = 25) PEXG (n = 24) NTG (n = 18) Control (n = 20) P value
Age range 44–78 48–79 50–71 50–67 0.71
Mean ± SD 56.76 ± 12.58 61.66 ± 10.05 57.77 ± 7.27 55.63 ± 4.04
Male 7 (28%) 10 (41.7%) 6 (33.3%) 5 (26.3%) 0.686
Female 18 (72%) 14 (58.3%) 12 (66.7%) 14 (73.7%)BMC Ophthalmology 2006, 6:6 http://www.biomedcentral.com/1471-2415/6/6
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ferences between groups. P value <0.05 was considered
statistically significant. Statistical analyses were performed
using software SPSS version 10.00.
Results
There were no significant differences in gender and age
between control group and the other groups (Table 1).
Levene's variance homogeneity analysis showed that the
variances of groups were homogenous in serum Hcy, vita-
min B12, folic acid, age and gender (P > 0.05).
The parametric one-way ANOVA test indicated that the
mean Hcy concentration in the PEXG group was signifi-
cantly higher (P < 0.001) than in the other groups. Mean
± standard deviation (SD) of Hcy levels in PEXG was
14.88 ± 3.26 µmol/l. The mean Hcy concentrations
among the other groups were not significantly different (P
> 0.05). Mean ± SD of Hcy levels in POAG, NTG and con-
trol subjects were 9.22 ± 3.70, 10.39 ± 2.89, 8.40 ± 2.77
µmol/l, respectively (Table 2, and Figure 1).
There were no statistical differences in serum vitamin B12
levels among POAG, PEXG, NTG and control subjects (P
> 0.05). Mean ± SD of vitamin B12 levels in POAG, PEXG,
NTG and control subjects were 209.37 ± 104.44, 232.84 ±
67.55, 262.33 ± 85.94, 261.84 ± 126.22 pg/ml, respec-
tively (Table 2, and Figure 2).
When all groups were compared, it has been found that
the mean serum folic acid level was significantly lower in
the subjects with PEXG (P < 0.009). Mean ± SD of folic
acid levels in PEXG was 4.26 ± 1.69 ng/ml. The mean folic
acid concentrations among the other groups were not sig-
nificantly different (P > 0.05). Mean ± SD of folic acid lev-
els in POAG, NTG and control subjects were 6.24 ± 2.88,
5.97 ± 1.85, 5.93 ± 1.70 ng/ml, respectively (Table 2, and
Figure 3).
Discussion
Some studies have demonstrated that Hcy induces over-
production of oxidative radicals which, in turn, causes
Table 2: Serum homocysteine, vitamin B 12 and folic acid levels in different types of glaucoma.
Patient Number Hcy(µmol/g) Vit.B12(pg/ml) Folate(ng/ml)
PEXG 24 14.88 ± 3.26* 209.37 ± 104.44 4.26 ± 1.69*
POAG 25 9.22 ± 3.70 232.84 ± 67.55 6.24 ± 2.88
NTG 18 10.39 ± 2.89 262.33 ± 85.94 5.97 ± 1.85
Control 19 8.40 ± 2.77 261.84 ± 126.22 5.93 ± 1.70
*Statistically significant
Serum Homocysteine Levels in Different Types of Glaucoma Figure 1
Serum Homocysteine Levels in Different Types of Glaucoma. 
Group 1: Primary Open-angel Glaucoma (POAG), Group 2: 
Pseudoexfoliative Glaucoma (PEXG), Group 3: Normoten-
sive Glaucoma (NTG), Group 4: Control Group.
Serum Vit Figure 2
Serum Vit. B 12 Levels in Different Types of Glaucoma. 
Group 1:PEXG, Group 2: POAG, Group 3: NTG, Group 4: 
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intimal damage and activate serine elastase in arterial
smooth muscle cells [8,20]. Activation of matrix metallo-
proteinase 2 causes elastolysis of elastin and fibrillar col-
lagen in arterial media [20]. Oxidative stress may explain
the effect of homocysteine in systemic vascular diseases.
Folic acid is able to scavenge oxygen radicals and
improves endothelial function [21]. Dietary folic acid
(0.5–5 mg/day) reduces basal Hcy levels by 25% [22].
In the current study, we found elevated serum Hcy levels
and reduced folic acid levels to be associated with PEXG
when compared with the other groups. No statistically sig-
nificant difference was found between plasma Hcy, folic
acid and vitamin B12 levels in POAG, NTG and control
patients.
Distribution circulation is involved in the pathogenesis of
glaucomatous damage [1]. The endothelium plays an
important role in the regulation of vascular tone. Hcy,
being one of the important vasoconstructive factors,
induces vascular oxidative stres [23]. PEX is also related
with oxidative stres [24]. It is also known that homo-
cysteine is a risc factor for atherosclerosis and chronic ele-
vation of plasma homocysteine impairs endothelium-
dependent vasodilatation [22]. The cause for this is an
inhibition of the NO-synthesis by asymmetric dimethyl-
arginine (ADMA). ADMA is increased by oxidative stress
and also by homocysteine [25]. This events may explain
the increased risk of vascular disease among patients with
PEXG.
We observed significantly elevated Hcy levels in plasma of
PEXG patients, which is in line with previous studies [15-
18]. PEX materials are deposited in the adventia of the iris
vessels associated with degeneration of endothelial cells.
The iris vasculopathy causes blood-aqueous barrier dys-
function and anterior segment hypopxia [26]. Since PEX is
a systemic disorder, this vasculopathy may also affect
other tissues of the body.
An association of exfoliative syndrome with branch and
central retinal vein occlusion has been suggested [27,28].
In the Blue Mountain Eye Study, exfoliation syndrome
correlated positively with a history of hypertension,
angina, myocardial infarction, or stroke [29]. In addition,
some studies have reported a higher frequency of exfolia-
tion syndrome in patients with abdominal aortic aneu-
rysm and transient ischemic attacks [30,31].
Although previous studies have reported elevated plasma
Hcy levels in PEXG, only Puustjarvi et al. measured eryth-
rocyte folic acid, serum vitamin B 12 and B6 levels, and
reported that the erythrocyte folic acid, serum vitamin
B12 and B6 levels did not differ statistically between PEXG
group and controls [15-18]. Our study demonstrates that
decreased serum folic acid levels occur only in PEXG
group, and that there was no significant difference in vita-
min B12 level among PEXG, POAG, NTG and control
groups. Further studies should be performed to demon-
strate whether the ocular and systemic ischemic changes
and neurodegeneration may be prevented or slowed
down in PEXG with folic acid supplementation.
Only one study reported elevated serum Hcy level in
POAG patients and suggested that thermolabile methyl-
enetetrahydrofolate reductase deficiency may be in part
the cause of the increased serum Hcy level in patient with
POAG [14]. We found that serum Hcy level in patients
with POAG did not statistically differ from the other
groups. This finding is supported with the study of Altin-
tas et al. [18] and Wang et al. [19].
Vessani et al. [16] suggested an elevated plasma Hcy level
is more common in PEXG patients than in control sub-
jects, but not in patients with NTG. We also find that
serum Hcy levels were not significantly different from the
other groups. In addition, there was no difference serum
vitamin B 12 and folic acid levels in this group.
To the best of our knowledge, this is the first study that has
compared Hcy, folic acid and vitamin B12 levels meas-
ured by the immunoassay method among patients with
PEXG, POAG, NTG and control groups.
Hyperhomocysteinemia is related with vascular dysfunc-
tion, glaucoma and pseudoexfoliative syndrome, but
whether it is as a cause or a consequence remains to be
clarified. These results suggested that a relationship only
with PEXG-associated systemic and ocular vasculopathy.
Further larger scale studies are needed to elucidate the role
of hyperhomocysteinemia in different types of glaucoma
Serum Folic Acid Levels in Different Types of Glaucoma Figure 3
Serum Folic Acid Levels in Different Types of Glaucoma. 
Group 1:PEXG, Group 2: POAG, Group 3: NTG, Group 4: 
Control.BMC Ophthalmology 2006, 6:6 http://www.biomedcentral.com/1471-2415/6/6
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due to evaluated levels of Hcy in plasma, ocular (aqueous
humour or vitreous), and the other tissues.
Conclusion
In our study, among various glaucoma types, only in
PEXG type serum levels of Hcy was found to be increased
and serum levels of folic acid was found to be decreased.
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